On August 21, 2020, the Drug Enforcement Administration (DEA)
published an interim final rule that may have far-reaching
consequences for the entire hemp and CBD industry. In addition to
modifying the definitions of "tetrahydrocannabinols"
(THC) and "marijuana extract" to exclude legal hemp, and
removing FDA-approved CBD-based drugs from scheduled control under
the Controlled Substances Act (CSA), the DEA announced a new rule
clarifying that all hemp derivatives or extracts
exceeding 0.3% delta-9 THC remain schedule I controlled
substances.
Although seemingly innocuous at first glance, this clarification
may potentially create a profound practical obstacle to the legal
manufacturing of most hemp-derived CBD products. As many processors
and extractors in the industry know, hemp extract that is not in
its final form almost invariably exceeds 0.3% delta-9 THC
concentration at some point during the extraction process before
that percentage is brought back into legal